Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide, dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018, 8(8):70. doi: 10.1038/s41408-018-0106-3.

Articles

---

October 24th 2018

Study Summary: Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma

Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide, dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018, 8(8):70. doi: 10.1038/s41408-018-0106-3.

Latest Updated Articles

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: December 19th 2024 | Updated: December 26th 2024

The Dangerous Intersection of Breast Cancer and Cardiovascular Disease: A Call for Improved Prevention